Fact CheckerSign in

NCT05859022Recruiting

Metabolic Effects of Bariatric Arterial Embolization vs Bariatric Surgery

Comparison of Metabolic Effects of Bariatric Arterial Embolization vs. Bariatric Surgery

Source: ClinicalTrials.gov · Last updated 11 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Obesity and Type 2 diabetes mellitus (DMT2) are two of the most common chronic diseases of the Western society. Obesity is one critical factor in DMT2 development, with weight loss having profound beneficial effects on DMT2 and improving the metabolic pathophysiology leading to hyperglycemia. Observational studies reported that surgical intervention of morbid obesity achieved significant improvement of resolution of DMT2, both in short and long-term. Bariatric surgery has been considered the best option for treatment of diabetic obese patients, with the laparoscopic Roux-en-Y Gastric Bypass being the gold standard of the surgical treatment. Bariatric arterial embolization (BAE) technique has proved to be safe effective for weight loss in obese patients, but its metabolic effects have not been studied yet. The hypothesis of the study is that BAE is effective for the resolution of DMT2 inpatients with BMI between 30-43 Kg/m2. The aim is to assess DMT2 remission after BAE and bariatric surgery, to analyze potential conditioning factors, and to compare remission criteria between bariatric surgery and BAE.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
3 Apr 2023
Start date
16 Jun 2021
Primary completion date
Aug 2025
Lead sponsor
Universidade Nova de Lisboa
Diseases
Obesity
NCT number
NCT05859022

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 16 Jun 2021 to the primary completion date, Aug 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior bariatric surgery of any kind.
  • Prior complex abdominal surgery including splenectomy, upper GI, anti-reflux surgery and trauma.
  • Abdominal, thoracic, pelvic and/or obstetric-gynaecologic surgery within 3 months or at the discretion of the surgery.
  • Cardiovascular conditions including uncompensated congestive heart failure, dysrhythmia, history of stroke, or uncontrolled hypertension (defined as medically treated with the mean of 3 separate measurements systolic blood pressure (SBP)\> 180 mmHg or diastolic blood pressure (DBP) \>110mmHg). Patients with coronary artery disease (CAD) that have been successfully treated with coronary artery by-pass graft (CABG) or percutaneous coronary intervention (PCI) or are 1 year after implantation of drug eluting stent and have no evidence of active ischemia are eligible.
  • Psychiatric disorders including dementia, active psychosis, severe depression requiring \>2 medications, history of suicide attempts, alcohol or drugs abuse with previous 12months.
  • Use of investigational therapy or participation in any other clinical trial within 12 weeks prior to signing the informed consent form.

Other illness

  • Known history of chronic liver disease (except for NAFLD/NASH), hepatitis, positive serologic test result for hepatitis B surface antigen and/or hepatitis C antibody, alpha-1-antitrypsin deficiency.
  • Gastrointestinal disorders including a known history of celiac disease and/or other malabsorptive disorders or inflammatory bowel disease (Chron's disease or ulcerative colitis).
  • Malignancy within 5 years (except squamous cell and basal cell cancer of skin).
  • Any medical condition requiring anticoagulation therapy that cannot be temporarily discontinued for surgical or embolic approach.
  • Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study.
  • Severe pulmonary disease.
  • History of allergy to iodinated contrast media

Lab values

  • Anaemia defined as haemoglobin less than 9 in females and 10 in males.

Other

  • Pregnancy.
  • American Society of Anesthesiologists (ASA) physical status class IV or higher.

Who the study is looking for

  • criteria:
    • Is the candidate for general anesthesia.
    • Body Mass Index (BMI) between 33 and 43 Kg/m2
    • Patients have a biochemical evidence of Type 2 Diabetes Mellitus (DMT2) confirmed by American Diabetes Association (ADA) criteria:
    • 3.1) treated - HbA1c 7,1%; 3.2) If untreated- fasting 2-hour plasma glucose level of 200 mg/dL during an oral glucose tolerance test and a HbA1c of 7,1%.
    • Willing, able, and mentally competent to provide written informed consent.
    • Able o understand the options and to comply with the requirements of each program.
    • Have a negative urine pregnancy test at screening and baseline visits (prior surgery and Embolization) for women of childbearing potential.
    • Female patients must agree to use reliable method of contraception for 2 years.

Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Cruz Vermelha Hospital
Coordinator of this site? Confirm its status
LisbonPortugalRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.